Bovine Interleukin 8,IL-8 ELISA Kit
- Known as:
- Bovine Interleukin 8,Interleukin-8 Enzyme-linked immunosorbent assay test Kit
- Catalog number:
- E0001BO
- Product Quantity:
- 48T
- Category:
- Elisa Kits
- Supplier:
- JING
- Gene target:
- Bovine Interleukin 8 IL-8 ELISA Kit
Related genes to: Bovine Interleukin 8,IL-8 ELISA Kit
- Gene:
- CXCL8 NIH gene
- Name:
- C-X-C motif chemokine ligand 8
- Previous symbol:
- IL8
- Synonyms:
- SCYB8, LUCT, LECT, MDNCF, TSG-1, IL-8, NAP-1, 3-10C, MONAP, AMCF-I, LYNAP, NAF, b-ENAP, GCP-1, K60, GCP1, NAP1
- Chromosome:
- 4q13.3
- Locus Type:
- gene with protein product
- Date approved:
- 1989-06-30
- Date modifiied:
- 2016-10-05
- Gene:
- CXCR1 NIH gene
- Name:
- C-X-C motif chemokine receptor 1
- Previous symbol:
- CMKAR1, IL8RA
- Synonyms:
- CKR-1, CDw128a, CD181
- Chromosome:
- 2q35
- Locus Type:
- gene with protein product
- Date approved:
- 1992-11-09
- Date modifiied:
- 2016-03-14
- Gene:
- CXCR2 NIH gene
- Name:
- C-X-C motif chemokine receptor 2
- Previous symbol:
- IL8RB
- Synonyms:
- CMKAR2, CD182
- Chromosome:
- 2q35
- Locus Type:
- gene with protein product
- Date approved:
- 1991-08-19
- Date modifiied:
- 2016-03-14
- Gene:
- CXCR2P1 NIH gene
- Name:
- C-X-C motif chemokine receptor 2 pseudogene 1
- Previous symbol:
- IL8RBP, CXCR2P
- Synonyms:
- -
- Chromosome:
- 2q35
- Locus Type:
- pseudogene
- Date approved:
- 1992-11-27
- Date modifiied:
- 2016-03-14
Related products to: Bovine Interleukin 8,IL-8 ELISA Kit
Related articles to: Bovine Interleukin 8,IL-8 ELISA Kit
- Acne vulgaris is characterized by microbial dysbiosis and excessive inflammatory activation, whereas current topical therapies are often limited by poor skin penetration and increasing antibiotic resistance. Ursodeoxycholic acid (UDCA) has anti-inflammatory potential but suffers from low aqueous solubility and limited cutaneous permeability. In this study, a co-amorphous salt of UDCA and matrine (MAT) was developed to improve the pharmaceutical performance of UDCA and to combine the complementary activities of the two components. UDCA-MAT was further incorporated into hyaluronic acid-based dissolving microneedles (UM-MNs) to enhance local transdermal delivery. FTIR, DSC, and PXRD confirmed amorphization and ionic interaction between UDCA and MAT. Compared with UDCA alone, UM increased the apparent aqueous solubility of UDCA by approximately 2302-fold and significantly improved ex vivo skin permeation. In vitro, UM showed stronger growth-inhibitory effects against Cutibacterium acnes within the tested concentration range and more effectively reduced the expression of IL1B, IL6, CXCL8, and TNF in stimulated HaCaT cells, accompanied by reduced NF-κB p65 nuclear translocation. In a murine acne model, UM was associated with reduced lesion size, bacterial burden, and inflammatory cytokine levels relative to the single-component groups under the present experimental conditions. UM-MNs showed adequate mechanical strength, achieved effective skin insertion, and enabled continued drug release over 24 h. Compared with topical gel, UM-MNs were associated with greater improvement in lesion morphology and local inflammatory status, together with reduced activation of the C. acnes-related TLR2/4-NF-κB pathway in vivo. These findings support a formulation-based, antibiotic-sparing strategy for acne treatment through co-amorphous salt engineering combined with microneedle-assisted delivery. - Source: PubMed
Publication date: 2026/04/21
Zhao YujiaSun YananPeng JuanGong JunxiaoRen XingGao XinyuYang ShuoLi LishuangMa YumanWang YiLiu Dongchun - Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a heterogeneous condition with limited ideal therapeutic options. Acupuncture has shown clinical benefits for CP/CPPS, yet its molecular basis remains insufficiently characterized. - Source: PubMed
Publication date: 2026/04/17
Liang ChengWang HaoChang HongyuanLiu MingWang Fu - - Source: PubMed
Publication date: 2026/04/22
Zhang ChengZhao ZhipengShi Dan - Developing reliable biomarkers capable of differentiating Parkinson's disease from other neurological conditions is crucial for both patient care and research. In this study, we leveraged recent advances in high-throughput proteomic technology and machine learning to develop candidate biomarkers for Parkinson's disease. Using the Olink Explore 3072 assay, we obtained plasma proteomic profiles from 698 study participants, comprising Parkinson's disease cases (n = 149), neurologically healthy controls (n = 230), and participants with other neurological conditions (n = 319). The study cohort was split into Training Set (n = 560) and Test Set (n = 138). We conducted differential protein abundance analysis and pathway enrichment analysis, and subsequently applied the Boruta algorithm to identify differentially abundant proteins that are predictive of Parkinson's disease. To create a diagnostic biomarker panel, we trained a stacking ensemble machine learning (ML) model on the Training Set (n = 118 Parkinson's patients, n = 184 healthy controls, and n = 258 individuals with other neurological disorders) using eleven proteins (APOH, ARG1, CCN1, CXCL1, CXCL8, DDC, GRAP2, IL1RAP, OSM, PRL, and SPRY2) as model features. We used the Shapley Additive Explanations (SHAP) framework and network analysis to evaluate predictive importance and biological relevance of each protein in the ML model. The model demonstrated high accuracy in the held-out Test Set (n = 138) and three external cohorts-the UK Biobank (n = 43,969), the Parkinson's Disease Biomarkers Program (n = 138), and the Parkinson's Progression Markers Initiative (n = 385), with areas under the receiver operating characteristic curve of 0.939, 0.789, 0.909, 0.816, respectively. Additionally, network and pathway analyses helped interpret the model, revealing activity related to inflammatory mediators, ErbB signaling, T-cell receptor signaling, and lipid metabolism. Our findings highlight the potential of plasma protein biomarkers to improve Parkinson's disease diagnosis and deepen biological understanding of this complex neurological disorder. Our model demonstrates high specificity and reliability across multiple independent cohorts, indicating the significant potential of proteomics-based biomarkers and the clinical utility of ML-supported diagnosis in Parkinson's disease care. The model also helps to elucidate potential novel risk factors and pathways associated with Parkinson's disease. - Source: PubMed
Publication date: 2026/04/22
Adewale BoluwatifeChia RuthMoaddel RuinLandeck NatalieRasheed MemoonaAlba CamilleReho PaoloVasta RosarioCalvo AndreaMoglia CristinaCanosa AntonioManera UmbertoSnyder AllisonLee Yi-JungGrassano MaurizioGao ChristineZhu MinBrunetti MauraCasale FedericoArvind Kumar Dawson Ted MRosenthal Liana SHall Anna JPantelyat Alexander YDing JinhuiGibbs J RaphaelEgan Josephine MCandia JuliánTanaka ToshikoFerrucci LuigiChiò AdrianoNarendra Derek PKwan Justin YEhrlich Debra JDalgard Clifton LTraynor Bryan JScholz Sonja W - To investigate the molecular mechanisms of Jianpi Yanggan Pill (JPYGP) in treating Diarrhea-predominant irritable bowel syndrome (IBS-D) using an integrated network pharmacology approach combined with experimental validation. - Source: PubMed
Publication date: 2026/03/15
Ma KeHua XiaokunLi ZhipengZhang ShenghuaZhu TingJin LinxiLi WeipingShao JingranLi XiangWen WeiboLuan Yunpeng